Equities

Procept Biorobotics Corp

PRCT:NMQ

Procept Biorobotics Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)82.79
  • Today's Change-0.18 / -0.22%
  • Shares traded645.24k
  • 1 Year change+149.52%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Company’s proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.

  • Revenue in USD (TTM)176.58m
  • Net income in USD-103.71m
  • Incorporated2021
  • Employees626.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
UFP Technologies Inc417.47m49.55m2.59bn3.09k52.728.3642.266.216.416.4154.0240.421.024.266.68134,971.5012.089.6913.8510.9528.0226.3311.8710.141.6321.630.10240.0013.0816.007.5025.7114.08--
10X Genomics Inc631.73m-239.78m2.66bn1.26k--3.67--4.21-2.02-2.025.316.010.65832.597.06501,773.60-24.99-25.52-28.04-29.0564.7075.88-37.96-48.534.42--0.00--19.8133.43-53.67--49.15--
LivaNova PLC1.21bn-16.59m2.77bn2.90k--2.2392.452.29-0.3133-0.313322.2922.880.50462.526.26417,149.00-0.6876-6.01-0.7843-7.4267.6466.99-1.36-13.562.942.190.3347--12.890.8278120.34---1.64--
Tandem Diabetes Care Inc796.00m-136.49m2.79bn2.40k--11.93--3.51-2.09-2.0912.213.570.84492.628.09331,667.50-14.49-10.08-18.58-12.2349.0651.77-17.15-11.592.38--0.598---6.6832.39-135.33--76.81--
Quidelortho Corp2.83bn-1.86bn3.11bn7.10k--0.9775--1.10-27.79-27.7942.3547.300.3722.589.15399,239.40-24.4011.34-27.5112.9147.8962.71-65.6020.930.79290.78950.44690.00-8.2141.83-101.84--45.87--
Envista Holdings Corp2.53bn-1.32bn3.30bn12.80k--1.11--1.30-7.70-7.7014.6417.320.42074.086.37197,937.50-21.981.94-26.292.3454.8957.65-52.255.291.903.920.33570.00-0.1012-2.04-142.10---4.22--
Axonics Inc408.81m-1.71m3.51bn797.00--5.45323.678.59-0.0291-0.02918.1112.610.58561.127.81512,934.80-0.2451-12.67-0.2618-13.7675.8970.04-0.4185-29.687.11--0.00--33.86249.0689.80--23.65--
Evolent Health Inc2.35bn-106.20m3.59bn4.70k--3.36234.281.52-0.9367-0.936720.7110.790.9191--6.55500,823.00-2.91-9.60-3.63-12.5918.5724.50-3.16-13.66---0.23820.326--45.2625.65-660.71---6.18--
Neogen Corp924.22m-9.42m3.74bn2.92k--1.1934.824.04-0.0435-0.04354.2714.510.2032.855.67316,839.90-0.2071.38-0.2141.4450.1948.23-1.024.312.591.190.22080.0012.3717.4158.81--50.02--
Haemonetics Corporation1.33bn114.89m3.87bn3.66k33.874.2717.732.902.232.2325.9217.700.59241.877.05364,751.205.105.025.746.0753.5851.748.618.112.3360.200.57470.0012.016.231.8716.40-11.04--
Procept Biorobotics Corp176.58m-103.71m4.27bn626.00--17.10--24.16-2.06-2.063.504.850.5461.853.83282,068.70-32.07---36.52--54.73---58.73--6.49--0.1696--81.55---21.51------
Integer Holdings Corp1.67bn105.37m4.30bn10.50k42.112.7720.592.583.053.0548.2746.340.55744.885.10158,938.203.523.283.783.5326.7726.946.316.401.963.670.42150.0016.035.6238.719.3321.71--
ICU Medical Inc2.30bn-70.79m4.30bn14.00k--2.1127.451.87-2.92-2.9294.9083.430.52672.1314.68164,591.20-1.621.46-1.831.6532.4734.11-3.072.231.080.55550.44120.00-0.915410.0460.08---1.45--
TransMedics Group Inc358.76m3.00m5.20bn584.003,779.9327.36299.0414.500.04130.041310.615.700.49523.565.58614,313.400.4141-16.080.4403-17.9560.7165.370.8362-40.478.48--0.7278--158.5379.3630.92--225.12--
DENTSPLY SIRONA Inc3.90bn-185.00m5.41bn15.00k--1.7733.021.39-0.8698-0.869818.6515.120.53562.946.18259,733.30-2.49-1.14-3.03-1.3252.2353.65-4.65-2.510.86923.650.4066--1.10-0.107186.11---4.549.86
Merit Medical Systems Inc1.30bn117.43m5.75bn6.95k49.204.4827.004.422.012.0122.2422.040.61832.307.36187,231.105.582.456.132.7746.5444.509.023.914.6417.520.38460.009.247.3326.7015.86-11.16--
Data as of Sep 19 2024. Currency figures normalised to Procept Biorobotics Corp's reporting currency: US Dollar USD

Institutional shareholders

46.88%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Jun 20247.23m13.91%
The Vanguard Group, Inc.as of 30 Jun 20244.59m8.84%
BlackRock Fund Advisorsas of 30 Jun 20243.13m6.02%
AllianceBernstein LPas of 30 Jun 20241.81m3.48%
T. Rowe Price Investment Management, Inc.as of 30 Jun 20241.75m3.36%
Champlain Investment Partners LLCas of 30 Jun 20241.37m2.63%
Loomis, Sayles & Co. LPas of 30 Jun 20241.26m2.43%
SSgA Funds Management, Inc.as of 30 Jun 20241.11m2.14%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 20241.08m2.09%
Geode Capital Management LLCas of 30 Jun 20241.02m1.97%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.